RP3

· Replimune, Inc.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for RP3, covering 2025-03-11 to 2026-02-27. Get the full timeline:

Most recent: Clinical Trial Update: Study of RP3 Monotherapy and RP3 in Combination With Nivolumab in Patients With Solid Tumours [Phase 1]